With the increasing importance of early diagnosis in disease, there is a need for quicker and easier diagnosis techniques. Various immunological diagnostic methods are being studied and developed. Advancement of diagnostic methods presents higher sensitivity, specificity and convenience.
GCMS Immunodiagnostics is continuously expanding its domestic market share on the basis of its diverse product portfolio. To target the immunodiagnostic market, the largest market in the global diagnostic reagent field, we take persistent efforts in development and diversification of our product portfolio. We will enhance our competitiveness and increase revenue by development of raw materials for diagnosis.
GCMS will be a domestically and globally well-recognized leading company dedicated to diagnostics.

Despite advancements in modern medicine, the number of patients suffering from diabetes and metabolic diseases continues to rise globally. These conditions require not only treatment but also long-term and systematic management. The GCMS BGMs Development Team is dedicated to addressing these global health challenges by researching and developing various electrochemical-based sensors, including blood glucose sensors, ketone sensors, uric acid sensors, and lactate sensors. We are constantly advancing sensor technologies to ensure accuracy and reliability, striving to establish a new paradigm for managing diabetes and metabolic diseases.
We remain committed to improving the quality of life for patients and leading innovation in the diagnostic field through continuous efforts and challenges.

Recently, the needs for POCT capable of rapid testing at the field are increasing. GC Green Cross Medical Science is developing highly reliable diagnostic devices. In addition, we expand our scope of R&D to data transmission using wireless communication and data management using cloud servers.